Molecular Involvement and Prognostic Importance of Fms-like Tyrosine Kinase 3 in Acute Myeloid Leukemia

被引:3
|
作者
Shahab, Sadaf [1 ]
Shamsi, Tahir S. [1 ]
Ahmed, Nuzhat [1 ]
机构
[1] Natl Inst Blood Dis & Bone Marrow Transplantat, Karachi, Pakistan
关键词
AML; FLT3; ITDs; (TKD); leukemia-specific recognition markers; prognostic marker; INTERNAL TANDEM DUPLICATION; FLT3; GENE; MYELODYSPLASTIC SYNDROME; MYELOGENOUS LEUKEMIA; NORMAL CYTOGENETICS; MUTATIONS; ASSOCIATION; IDENTIFICATION; ACTIVATION; EXPRESSION;
D O I
10.7314/APJCP.2012.13.8.4215
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
AML (Acute myeloid leukemia) is a form of blood cancer where growth of myeloid cells occurs in the bone marrow. The prognosis is poor in general for many reasons. One is the presence of leukaemia-specific recognition markers such as FLT3 (fms-like tyrosine kinase 3). Another name of FLT3 is stem cell tyrosine kinase-1 (STK1), which is known to take part in proliferation, differentiation and apoptosis of hematopoietic cells, usually being present on haemopoietic progenitor cells in the bone marrow. FLT3 act as an independent prognostic factor for AML. Although a vast literature is available about the association of FLT3 with AML there still is a need of a brief up to date overview which draw a clear picture about this association and their effect on overall survival.
引用
收藏
页码:4215 / 4220
页数:6
相关论文
共 50 条
  • [1] Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia
    Swords, R.
    Freeman, C.
    Giles, F.
    LEUKEMIA, 2012, 26 (10) : 2176 - 2185
  • [2] FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
    Novatcheva, Elli D.
    Anouty, Yasmine
    Saunders, Ila
    Mangan, James K.
    Goodman, Aaron M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : E161 - E184
  • [3] Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia
    R Swords
    C Freeman
    F Giles
    Leukemia, 2012, 26 : 2176 - 2185
  • [4] Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
    Pemmaraju, Naveen
    Kantarjian, Hagop
    Andreeff, Michael
    Cortes, Jorge
    Ravandi, Farhad
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (07) : 943 - 954
  • [5] FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia
    Parcells, Bertrand W.
    Ikeda, Alan K.
    Simms-Waldrip, Tiffany
    Moore, Theodore B.
    Sakamoto, Kathleen M.
    STEM CELLS, 2006, 24 (05) : 1174 - 1184
  • [6] Fms-Like Tyrosine Kinase 3 Mutations in Childhood Acute Leukemias and their Association with Prognosis
    Karabacak, Bircan Hizli
    Erbey, Fatih
    Bayram, Ibrahim
    Yilmaz, Sema
    Acipayam, Can
    Kilinc, Yurdanur
    Tanyeli, Atila
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2010, 11 (04) : 923 - 927
  • [7] Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia
    Pazhakh, Vahid
    Zaker, Farhad
    Alimoghaddam, Kamran
    Atashrazm, Farzaneh
    ANNALS OF SAUDI MEDICINE, 2011, 31 (01) : 45 - 50
  • [8] FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile
    Garciaz, Sylvain
    Hospital, Marie-Anne
    ONCOTARGETS AND THERAPY, 2023, 16 : 31 - 45
  • [9] Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients
    Reed, Daniel R.
    Sen, Jeremy M.
    Pierce, Eric J.
    Elsarrag, Ramey Z.
    Keng, Michael K.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (05) : 1200 - 1212
  • [10] Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia
    Prescott, Hillary
    Kantarjian, Hagop
    Cortes, Jorge
    Ravandi, Farhad
    EXPERT OPINION ON EMERGING DRUGS, 2011, 16 (03) : 407 - 423